Rating scales for cervical dystonia: A critical evaluation of tools for outcome assessment of botulinum toxin therapy

Journal of Neural Transmission

Volumn 120, Issue 3, 2013, Pages 487-496

  Jost, Wolfgang H ^a   Hefter, Harald ^b   Stenner, Andrea ^c   Reichel, Gerhard ^c  

^a DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Paracelsus Clinic   (Germany)

Author keywords

Botulinum toxin; Cervical dystonia; Outcome assessment; Rating scales

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

CERVICAL DYSTONIA; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPARATIVE STUDY; DISEASE CLASSIFICATION; HEAD MOVEMENT; HUMAN; MUSCLE SPASM; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME; TREMOR; VISUAL ANALOG SCALE;

BOTULINUM TOXINS; HUMANS; NEUROMUSCULAR AGENTS; SEVERITY OF ILLNESS INDEX; TORTICOLLIS; TREATMENT OUTCOME;

EID: 84875701964     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0887-7     Document Type: Review

References (45)

1. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949-1951 (Pubitemid 40800714)
2. Blackie JD, Lees AJ (1990) Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 53(8):640-643 (Pubitemid 20253527)
3. Brans JW, Lindeboom R, Snoek JW, Zwarts MJ, van Weerden TW, Brunt ER, van Hilten JJ, van der Kamp W, Prins MH, Speelman JD (1996) Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 46(4):1066-1072 (Pubitemid 26134654)
4. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53(7):1439-1446 (Pubitemid 29491934)
5. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53(7):1431-1438 (Pubitemid 29491933)
6. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J (1985) Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 35(1):73-77 (Pubitemid 15193623)
7. Cano SJ, Warner TT, Linacre JM, Bhatia KP, Thompson AJ, Fitzpatrick R, Hobart JC (2004a) Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58). Neurology 63(9):1629-1633 (Pubitemid 39507580)
8. Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT (2004b) Patient-based outcomes of cervical dystonia: a review of rating scales. Mov Disord 19(9):1054-1059 (Pubitemid 39302838)
9. Cano SJ, Hobart JC, Edwards M, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT (2006) CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology 67(12):2230-2232 (Pubitemid 46035484)
10. Chan J, Brin MF, Fahn S (1991) Idiopathic cervical dystonia - clinical characteristics. Mov Disord 6:119-126
11. Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG (1992) Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 42(4):878-882
12. Comella CL, Stebbins GT, Goetz CG, Chmura TA, Bressman SB, Lang AE (1997) Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord 12(4):570-575 (Pubitemid 27322887)
13. Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T, Dystonia Study Group (2003) Rating scales for dystonia: a multicenter assessment. Mov Disord 18(3):303-312 (Pubitemid 36410827)
14. Consky ES, Lang AE (1994) Clinical assessments of patients with cervical dystonia. In: Jancovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York, pp 211-237
15. Consky ES, Basinki A, Belle L, Ranawaya R, Lang AE (1990) The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability. Neurology 40(suppl 1):445
16. Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005a) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 25(1):CD003633
17. Costa J, Borges A, Espírito-Santo C, Ferreira J, Coelho M, Moore P, Sampaio C (2005b) Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 25(1):CD004314
18. Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005c) Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 25(1):CD004315
19. Dubinsky RM, Gray CS, Vetere-Overfield B, Koller WC (1991) Electromyographic guidance of botulinum toxin treatment in cervical dystonia. Clin Neuropharmacol 14(3):262-267
20. Fahn S (1989) Assessment of primary dystonias. In: Munsat TL (ed) Quantification of neurologic deficit. Butterworths, London, pp 241-270
21. Gelb DJ, Lowenstein DH, Aminoff MJ (1989) Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 39(1):80-84
22. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E (1990) Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40(8):1213-1218 (Pubitemid 20244977)
23. Jankovic J, Tolosa E (2007) Parkinsons's disease and movement disorders, 5th edn. Lippincott Williams & Wilkins, Philadelphia
24. Kamm C, Benecke R (2011) Botulinum toxin therapy for cervical dystonia: review of the clinical evidence and ongoing studies. Clin Invest 1(6):891-900
25. Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, Brin MF, Jankovic J, Rodnitzky RL, Singer C, Swenson MR, Tarsy D, Murray JJ, Koller M, Wallace JD (1997) Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49(3):701-707 (Pubitemid 27428008)
26. Lindeboom R, Brans JW, Aramideh M, Speelman HD, De Haan RJ (1998) Treatment of cervical dystonia: a comparison of measures for outcome assessment. Mov Disord 13(4):706-712 (Pubitemid 28334107)
27. Moore AP, Blumhardt LD (1991) A double blind trial of botulinum toxin "A" in torticollis, with one year follow up. J Neurol Neurosurg Psychiatry 54(9):813-816
28. Müller J, Wissel J, Kemmler G, Voller B, Bodner T, Schneider A, Wenning GK, Poewe W (2004) Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry 75(5):749-753 (Pubitemid 38526688)
29. O'Brien C, Brashear A, Cullis P, Truong D, Molho E, Jenkins S, Wojcieszek J, O'Neil T, Factor S, Seeberger L (2001) Cervical dystonia severity scale reliability study. Mov Disord 16(6):1086-1090 (Pubitemid 36041220)
30. Odergren T, Tollbäck A, Borg J (1994) Efficacy of botulinum toxin for cervical dystonia. A comparison of methods for evaluation. Scand J Rehabil Med 26(4):191-195 (Pubitemid 24376082)
31. Pappert EJ, Germanson T, Myobloc/Neurobloc European Cervical Dystonia Study Group (2008) Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 23(4):510-517
32. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, Künig G, German Dystonia Study Group (1998) What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry 64(1):13-17 (Pubitemid 28156531)
33. Reichel G (2011) Cervical dystonia: a new phenomenological classification for botulinum toxin therapy. Basal Ganglia 1:5-12
34. Scientific Advisory Group of the Medical Outcomes Trust (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 11(3):193-205 (Pubitemid 34553501)
35. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallet M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1699-1706 (Pubitemid 351644138)
36. Slawek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, Ochudlo S, Budrewicz S, Reclawowicz D, Rynkowski M, Opala G (2007) Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol 22(2):95-100 (Pubitemid 47249614)
37. Sommer S, Viga R, Petersen H, Koletzki E, Jost W (2009) Zerviton: a new tool to measure head position in patients with cervical dystonia: preliminary results. Mov Disord 24(Suppl 1):117-118
38. Stell R, Thompson PD, Marsden CD (1988) Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry 51(7):920-923
39. Tarsy D (1997) Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord 12(1):100-102 (Pubitemid 27032887)
40. Truong DD, Jost WH (2006) Botulinum toxin: clinical use. Parkinsonism Relat Disord 12(6):331-355 (Pubitemid 44189903)
41. Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL (2005) Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 20(7):783-791 (Pubitemid 41227144)
42. Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB (1985) A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 12(4):314-316 (Pubitemid 16198560)
43. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2(8501):245-247
44. Tsui JK, Fross RD, Calne S, Calne DB (1987) Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci 14(3 Suppl):533-555
45. Weiner WJ, Lang AE (1989) Movement disorders: a comprehensive survey. Futura, Mount Kisco, NY